Friedmans original GoodHormoneHealth Webinar on November 17, 2024 on compounded Tirzepatide vs Semaglutide for patients with endocrine problems or on your podcast channel
In terms of drug discovery, the lack of an optimal preclinical model in PD which faithfully resembles in vivo pathophysiology is one of its main limiting factors
hypothesized the central role of acrolein in the disruption of the structure of cell membranes in RBCs (changes in the cell membrane, cytosolic proteins, and osmotic sensitivity)
It's just another whack, she said
Graphical abstract Similar content being viewed by others Introduction Sodiumglucose co-transporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been shown to reduce the incidence of cardiovascular and kidney disease in people with type 2 diabetes, ostensibly independent of their effects on blood glucose [1, 2]
So why do some patients fail to respond Read More GLP-1 Therapy in Multimorbidity: Managing Complexity in the Real World Mar 30, 2026 Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Obesity, Therapies, Type 2 Diabetes, Type 2 Diabetes 684 views As the use of GLP-1 receptor agonists expands, clinicians increasingly face a key challenge: how do you manage patients with multimorbidity using GLP-1 therapies
.png)
